Intimation about the Outcome of the Board Meeting held on July 29, 2025, inter alia for the approval of the unaudited Financial Statements for the Quarter ending as on June 30, 2025.
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's Board approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from Operations stood at ₹875.5 million, down about 5% from ₹922.9 million in the same quarter last year. However, Profit After Tax rose to ₹276.2 million from ₹257.4 million, a growth of roughly 7%, helped by lower purchase costs and employee expenses. Earnings per Share came in at ₹11.19 versus ₹10.42 a year earlier. The statutory auditors B S R & Co. LLP issued a clean limited review report with no qualifications or adverse comments. The Board also appointed M/s. D. C. Dave & Co. as Cost Auditors for FY 2025-26 at a fee of ₹1.5 lakh and approved a postal ballot to seek shareholder ratification of this remuneration.
Modest top-line pressure but improved profitability and margins suggest better cost management; results are in line with routine quarterly disclosure and unlikely to move the stock sharply.